May 30, 2019 09:22 AM EDTUpdated May 31, 08:28 AM

Let's talk AI: Top R&D execs tackle where we are and where we're headed with this crucial new technology

As a biotech exec with a background in computational chemistry, Rosana Kapeller has been watching the hubbub over artificial intelligence and machine learning in biopharma play out with a considerable degree of skepticism.

“People talk about ML and AI without knowing what they are talking about,” the outspoken Nimbus alum told me earlier in the week. And there are some big pitfalls the uninitiated are likely to drop into without warning if they follow the crowd into AI without thinking things through first.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE

TRENDING NOW

Let's talk AI: Top R&D execs tackle where we are and where we're headed with this crucial new technology

This article is for premium subscribers only

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa

Let's talk AI: Top R&D ex­ecs tack­le where we are and where we're head­ed with this cru­cial new tech­nol­o­gy

This article is for premium subscribers only

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Roche's Genen­tech touts la­bel ex­pan­sion for block­buster lung can­cer drug Ale­cen­sa

Let's talk AI: Top R&D execs tackle where we are and where we're headed with this crucial new technology

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Roche's Genentech touts label expansion for blockbuster lung cancer drug Alecensa